Chesapeake IRB Completes Acquisition of IRB Services
Adds largest independent and only AAHRPP-accredited Canadian IRB/REB to the Chesapeake IRB organization
Jeff Wendel, President of Chesapeake IRB, said, “Adding IRB Services to our team is the realization of a long time goal for us, because it offers our clients a combined North American expertise and service capability that is unparalleled in our industry. IRB Services’ outstanding reputation and long standing dedication to the protection of human subjects participating in research across Canada enhances Chesapeake IRB’s services and capabilities.”
IRB Services, the largest independent and only AAHRPP-accredited Canadian IRB/REB, founded in 1993, will retain its name, leadership, and Canadian location, operating as a wholly-owned subsidiary of Chesapeake IRB.
The combination of two highly regarded, AAHRPP accredited organizations will efficiently deliver a unique solution to organizations conducting research in Canada and the US.
Jack Corman, Founder and CEO of IRB Services, said, “We are delighted to be able to come together with a like-minded organization; one that places the highest emphasis on integrity and quality in its service offering. In addition, we are looking forward to leveraging the CIRBI electronic submission platform to create a truly superlative IRB offering to our clients.”
Elyse Summers, President and CEO,
For questions regarding Chesapeake IRB or IRB Services please contact:
Jeffrey Wendel – President, Chesapeake IRB (410) 884-2900
Jack Corman – Managing Director, IRB Services (905) 727- 7989
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025